ELANCO ANIMAL HEALTH INC (ELAN) Stock Fundamental Analysis

NYSE:ELAN • US28414H1032

26.09 USD
-0.31 (-1.17%)
At close: Mar 2, 2026
26.03 USD
-0.06 (-0.23%)
After Hours: 3/2/2026, 7:15:26 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Taking everything into account, ELAN scores 4 out of 10 in our fundamental rating. ELAN was compared to 193 industry peers in the Pharmaceuticals industry. ELAN has an average financial health and profitability rating. ELAN has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • In the past year ELAN was profitable.
  • In the past year ELAN had a positive cash flow from operations.
  • ELAN had negative earnings in 4 of the past 5 years.
  • In the past 5 years ELAN always reported a positive cash flow from operatings.
ELAN Yearly Net Income VS EBIT VS OCF VS FCFELAN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M -1B

1.2 Ratios

  • The Return On Assets of ELAN (-1.74%) is better than 76.17% of its industry peers.
  • ELAN has a better Return On Equity (-3.54%) than 78.24% of its industry peers.
  • ELAN has a better Return On Invested Capital (1.48%) than 78.76% of its industry peers.
  • ELAN had an Average Return On Invested Capital over the past 3 years of 1.58%. This is significantly below the industry average of 12.91%.
Industry RankSector Rank
ROA -1.74%
ROE -3.54%
ROIC 1.48%
ROA(3y)-2.54%
ROA(5y)-2.21%
ROE(3y)-5.93%
ROE(5y)-5.05%
ROIC(3y)1.58%
ROIC(5y)1.62%
ELAN Yearly ROA, ROE, ROICELAN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 -5 -10 -15

1.3 Margins

  • ELAN's Operating Margin of 5.34% is amongst the best of the industry. ELAN outperforms 80.31% of its industry peers.
  • ELAN's Operating Margin has declined in the last couple of years.
  • ELAN has a Gross Margin of 54.99%. This is in the better half of the industry: ELAN outperforms 67.88% of its industry peers.
  • ELAN's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 5.34%
PM (TTM) N/A
GM 54.99%
OM growth 3Y-15.01%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.97%
GM growth 5Y2.32%
ELAN Yearly Profit, Operating, Gross MarginsELAN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • ELAN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, ELAN has more shares outstanding
  • The number of shares outstanding for ELAN has been increased compared to 5 years ago.
  • Compared to 1 year ago, ELAN has an improved debt to assets ratio.
ELAN Yearly Shares OutstandingELAN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M
ELAN Yearly Total Debt VS Total AssetsELAN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.2 Solvency

  • Based on the Altman-Z score of 1.51, we must say that ELAN is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of ELAN (1.51) is better than 60.10% of its industry peers.
  • The Debt to FCF ratio of ELAN is 14.14, which is on the high side as it means it would take ELAN, 14.14 years of fcf income to pay off all of its debts.
  • ELAN has a better Debt to FCF ratio (14.14) than 79.27% of its industry peers.
  • ELAN has a Debt/Equity ratio of 0.60. This is a neutral value indicating ELAN is somewhat dependend on debt financing.
  • ELAN has a Debt to Equity ratio of 0.60. This is in the lower half of the industry: ELAN underperforms 65.28% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF 14.14
Altman-Z 1.51
ROIC/WACC0.17
WACC8.59%
ELAN Yearly LT Debt VS Equity VS FCFELAN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B 6B 8B

2.3 Liquidity

  • A Current Ratio of 2.17 indicates that ELAN has no problem at all paying its short term obligations.
  • ELAN has a Current ratio (2.17) which is in line with its industry peers.
  • ELAN has a Quick Ratio of 1.08. This is a normal value and indicates that ELAN is financially healthy and should not expect problems in meeting its short term obligations.
  • ELAN has a Quick ratio of 1.08. This is in the lower half of the industry: ELAN underperforms 76.17% of its industry peers.
Industry RankSector Rank
Current Ratio 2.17
Quick Ratio 1.08
ELAN Yearly Current Assets VS Current LiabilitesELAN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 4.40% over the past year.
  • ELAN shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 15.11% yearly.
  • Looking at the last year, ELAN shows a small growth in Revenue. The Revenue has grown by 6.22% in the last year.
  • Measured over the past years, ELAN shows a small growth in Revenue. The Revenue has been growing by 7.59% on average per year.
EPS 1Y (TTM)4.4%
EPS 3Y-5.06%
EPS 5Y15.11%
EPS Q2Q%-7.14%
Revenue 1Y (TTM)6.22%
Revenue growth 3Y2.25%
Revenue growth 5Y7.59%
Sales Q2Q%12.16%

3.2 Future

  • Based on estimates for the next years, ELAN will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.51% on average per year.
  • The Revenue is expected to grow by 4.39% on average over the next years.
EPS Next Y10.05%
EPS Next 2Y11.47%
EPS Next 3Y13.05%
EPS Next 5Y10.51%
Revenue Next Year5.8%
Revenue Next 2Y5.53%
Revenue Next 3Y5.12%
Revenue Next 5Y4.39%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ELAN Yearly Revenue VS EstimatesELAN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2B 4B 6B
ELAN Yearly EPS VS EstimatesELAN Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 27.46 indicates a quite expensive valuation of ELAN.
  • ELAN's Price/Earnings ratio is a bit cheaper when compared to the industry. ELAN is cheaper than 79.27% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of ELAN to the average of the S&P500 Index (27.13), we can say ELAN is valued inline with the index average.
  • ELAN is valuated rather expensively with a Price/Forward Earnings ratio of 24.95.
  • ELAN's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. ELAN is cheaper than 75.65% of the companies in the same industry.
  • ELAN's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 28.11.
Industry RankSector Rank
PE 27.46
Fwd PE 24.95
ELAN Price Earnings VS Forward Price EarningsELAN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ELAN is valued cheaper than 81.87% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, ELAN is valued a bit cheaper than the industry average as 78.24% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 45.64
EV/EBITDA 17.8
ELAN Per share dataELAN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ELAN does not grow enough to justify the current Price/Earnings ratio.
  • ELAN's earnings are expected to grow with 13.05% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.73
PEG (5Y)1.82
EPS Next 2Y11.47%
EPS Next 3Y13.05%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ELAN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ELANCO ANIMAL HEALTH INC

NYSE:ELAN (3/2/2026, 7:15:26 PM)

After market: 26.03 -0.06 (-0.23%)

26.09

-0.31 (-1.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-24
Earnings (Next)05-05
Inst Owners116.54%
Inst Owner Change-10.47%
Ins Owners0.99%
Ins Owner Change4.72%
Market Cap12.96B
Revenue(TTM)4.71B
Net Income(TTM)-232.00M
Analysts85.45
Price Target27.2 (4.25%)
Short Float %4.73%
Short Ratio4.49
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)28.98%
Min EPS beat(2)15.04%
Max EPS beat(2)42.93%
EPS beat(4)4
Avg EPS beat(4)26.36%
Min EPS beat(4)15.04%
Max EPS beat(4)42.93%
EPS beat(8)7
Avg EPS beat(8)19.17%
EPS beat(12)10
Avg EPS beat(12)41.51%
EPS beat(16)13
Avg EPS beat(16)37.85%
Revenue beat(2)2
Avg Revenue beat(2)2.33%
Min Revenue beat(2)2.06%
Max Revenue beat(2)2.6%
Revenue beat(4)4
Avg Revenue beat(4)1.81%
Min Revenue beat(4)0.08%
Max Revenue beat(4)2.6%
Revenue beat(8)6
Avg Revenue beat(8)0.67%
Revenue beat(12)10
Avg Revenue beat(12)1%
Revenue beat(16)10
Avg Revenue beat(16)0.22%
PT rev (1m)4.42%
PT rev (3m)11.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.19%
EPS NY rev (1m)0%
EPS NY rev (3m)3.77%
Revenue NQ rev (1m)0.09%
Revenue NQ rev (3m)0.09%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.41%
Valuation
Industry RankSector Rank
PE 27.46
Fwd PE 24.95
P/S 2.75
P/FCF 45.64
P/OCF 23.15
P/B 1.98
P/tB N/A
EV/EBITDA 17.8
EPS(TTM)0.95
EY3.64%
EPS(NY)1.05
Fwd EY4.01%
FCF(TTM)0.57
FCFY2.19%
OCF(TTM)1.13
OCFY4.32%
SpS9.49
BVpS13.18
TBVpS-3.3
PEG (NY)2.73
PEG (5Y)1.82
Graham Number16.78
Profitability
Industry RankSector Rank
ROA -1.74%
ROE -3.54%
ROCE 2.14%
ROIC 1.48%
ROICexc 1.56%
ROICexgc 5.76%
OM 5.34%
PM (TTM) N/A
GM 54.99%
FCFM 6.02%
ROA(3y)-2.54%
ROA(5y)-2.21%
ROE(3y)-5.93%
ROE(5y)-5.05%
ROIC(3y)1.58%
ROIC(5y)1.62%
ROICexc(3y)1.64%
ROICexc(5y)1.68%
ROICexgc(3y)6.4%
ROICexgc(5y)7.61%
ROCE(3y)2.28%
ROCE(5y)2.34%
ROICexgc growth 3Y-17.32%
ROICexgc growth 5YN/A
ROICexc growth 3Y-7.69%
ROICexc growth 5YN/A
OM growth 3Y-15.01%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.97%
GM growth 5Y2.32%
F-Score5
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF 14.14
Debt/EBITDA 4.23
Cap/Depr 40.59%
Cap/Sales 5.85%
Interest Coverage 250
Cash Conversion 60.09%
Profit Quality N/A
Current Ratio 2.17
Quick Ratio 1.08
Altman-Z 1.51
F-Score5
WACC8.59%
ROIC/WACC0.17
Cap/Depr(3y)29.03%
Cap/Depr(5y)28.32%
Cap/Sales(3y)4.32%
Cap/Sales(5y)4.25%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.4%
EPS 3Y-5.06%
EPS 5Y15.11%
EPS Q2Q%-7.14%
EPS Next Y10.05%
EPS Next 2Y11.47%
EPS Next 3Y13.05%
EPS Next 5Y10.51%
Revenue 1Y (TTM)6.22%
Revenue growth 3Y2.25%
Revenue growth 5Y7.59%
Sales Q2Q%12.16%
Revenue Next Year5.8%
Revenue Next 2Y5.53%
Revenue Next 3Y5.12%
Revenue Next 5Y4.39%
EBIT growth 1Y0.4%
EBIT growth 3Y-13.1%
EBIT growth 5YN/A
EBIT Next Year40.58%
EBIT Next 3Y19.2%
EBIT Next 5Y12.62%
FCF growth 1Y-25.26%
FCF growth 3Y1.95%
FCF growth 5YN/A
OCF growth 1Y3.51%
OCF growth 3Y7.4%
OCF growth 5YN/A

ELANCO ANIMAL HEALTH INC / ELAN FAQ

What is the ChartMill fundamental rating of ELANCO ANIMAL HEALTH INC (ELAN) stock?

ChartMill assigns a fundamental rating of 4 / 10 to ELAN.


Can you provide the valuation status for ELANCO ANIMAL HEALTH INC?

ChartMill assigns a valuation rating of 4 / 10 to ELANCO ANIMAL HEALTH INC (ELAN). This can be considered as Fairly Valued.


Can you provide the profitability details for ELANCO ANIMAL HEALTH INC?

ELANCO ANIMAL HEALTH INC (ELAN) has a profitability rating of 5 / 10.


Can you provide the financial health for ELAN stock?

The financial health rating of ELANCO ANIMAL HEALTH INC (ELAN) is 4 / 10.


Can you provide the expected EPS growth for ELAN stock?

The Earnings per Share (EPS) of ELANCO ANIMAL HEALTH INC (ELAN) is expected to grow by 10.05% in the next year.